Related Experiment Video
Updated: Aug 14, 2025

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Use of Antiviral Agents and other Therapies for COVID-19
Mark A T Blaskovich1, Anthony D Verderosa1
1Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, Australia.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic led to a remarkably rapid development of a range of effective prophylactic vaccines, including new technologies that had not previously been approved for human use. In contrast, the development of new small molecule antiviral therapeutics has taken years to produce the first approved drugs specifically targeting severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), with the intervening years filled with attempts to repurpose existing drugs and the development of biological therapeutics. This review will discuss the reasons behind this variation in timescale and provide a survey of the many new treatments that are progressing through the clinical pipeline.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Subviral Agents
Myocarditis III: Medical Management
Drug Therapy
Antianxiety Medications
Microorganisms in Medicine and Therapeutics
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

